statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, July 18...

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?

Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and...

Amylyx Pharmaceuticals Inc: Strong Buy Rating on Avexitide's Potential and Strategic Pipeline Expansion

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX Research Report) and keeping the price targe...

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. (Eiger). Avexitide has been studied for the...

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that Amylyx management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00...

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare...

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial results for the first quarter ended March 31, 2024. As an organization deeply committed to ending the...

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of...

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx senior management team will host a conference...

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol...

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Volume	809,229.00
52-Wk High	$23.72
52-Wk Low	$1.58

AMLX Amylyx Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals